Biocytogen Pharmaceuticals (Beijing) (SHA:688796, HKG:2315) said its H shares were added to the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect programs, according to a Hong Kong bourse filing Wednesday.
The inclusion will allow investors in mainland China to directly deal in the H shares of the firm listed in Hong Kong.
Biocytogen Pharmaceuticals also recently made its debut on the Shanghai Stock Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments